AU2006206423A1 - Pharmaceutical formulations and methods of use - Google Patents

Pharmaceutical formulations and methods of use Download PDF

Info

Publication number
AU2006206423A1
AU2006206423A1 AU2006206423A AU2006206423A AU2006206423A1 AU 2006206423 A1 AU2006206423 A1 AU 2006206423A1 AU 2006206423 A AU2006206423 A AU 2006206423A AU 2006206423 A AU2006206423 A AU 2006206423A AU 2006206423 A1 AU2006206423 A1 AU 2006206423A1
Authority
AU
Australia
Prior art keywords
composition
gabapentin
active ingredient
independent
tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006206423A
Other languages
English (en)
Inventor
Rodney A. Brown
Stephen H. Curry
Michael Rubenstein
Michael R. Violante
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quay Pharmaceuticals Ltd
Pharmanova Inc
Original Assignee
Quay Pharmaceuticals Ltd
Pharmanova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36692870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2006206423(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Quay Pharmaceuticals Ltd, Pharmanova Inc filed Critical Quay Pharmaceuticals Ltd
Publication of AU2006206423A1 publication Critical patent/AU2006206423A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2006206423A 2005-01-21 2006-01-20 Pharmaceutical formulations and methods of use Abandoned AU2006206423A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64585705P 2005-01-21 2005-01-21
US60/645,857 2005-01-21
PCT/US2006/001887 WO2006078811A2 (en) 2005-01-21 2006-01-20 Pharmaceutical formulations and methods of use

Publications (1)

Publication Number Publication Date
AU2006206423A1 true AU2006206423A1 (en) 2006-07-27

Family

ID=36692870

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006206423A Abandoned AU2006206423A1 (en) 2005-01-21 2006-01-20 Pharmaceutical formulations and methods of use

Country Status (12)

Country Link
EP (1) EP1838291A4 (es)
JP (1) JP2008528494A (es)
KR (1) KR20070116588A (es)
CN (1) CN101137352A (es)
AR (1) AR062647A1 (es)
AU (1) AU2006206423A1 (es)
BR (1) BRPI0614021A2 (es)
CA (1) CA2595470A1 (es)
IL (1) IL184735A0 (es)
MX (1) MX2007008833A (es)
TW (1) TW200640497A (es)
WO (1) WO2006078811A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077599A1 (en) 2006-12-22 2008-07-03 Recordati Ireland Limited COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NSAIDS
WO2009066325A1 (en) * 2007-11-23 2009-05-28 Lupin Limited Controlled release pharmaceutical compositions of pregabalin
CA2706596A1 (en) * 2007-11-23 2009-05-28 Protect Pharmaceutical Corporation Tapentadol compositions
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
PT2661266T (pt) 2011-01-07 2020-11-30 Anji Pharma Us Llc Terapias com base em ligandos do recetor quimiossensorial
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
LT2704698T (lt) * 2011-05-05 2019-11-25 Hennig Arzneimittel Gmbh&Co Kg Vaisto forma, skirta aktyvių ingredientų kontroliuojamam atpalaidavimui
KR101438546B1 (ko) * 2011-08-26 2014-09-17 근화제약주식회사 프레가발린을 포함하는 서방성 제제
WO2013100873A1 (en) * 2011-12-19 2013-07-04 Mahmut Bilgic Pharmaceutical formulation of pregabalin (particle size 300-2500 micrometer)
EA201491335A1 (ru) 2012-01-06 2015-04-30 Элселикс Терапьютикс, Инк. Бигуанидные композиции и способы лечения метаболических расстройств
CN110693867A (zh) * 2012-01-06 2020-01-17 埃尔舍利克斯治疗公司 用于治疗代谢性病症的组合物和方法
KR102221846B1 (ko) * 2014-04-07 2021-02-26 영진약품 주식회사 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법
WO2016032000A1 (ja) * 2014-08-29 2016-03-03 わかもと製薬株式会社 乳酸菌含有組成物
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
WO2016187718A1 (en) * 2015-05-26 2016-12-01 Isa Odidi Controlled extended release pregabalin
TW201739455A (zh) 2016-04-19 2017-11-16 菲林公司 菸鹼醯胺的口服醫藥組成物
US11026908B2 (en) * 2016-07-17 2021-06-08 Mapi Pharma Ltd. Extended release dosage forms of pregabalin
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN112023032B (zh) * 2020-09-14 2022-03-18 广东鼎信医药科技有限公司 一种含有消化酶的药物组合物及其制备方法
JP2024504902A (ja) 2020-12-04 2024-02-02 ラボラトリオス シラネス、エセ．ア．デ セ．べ． 痛みに対するオピオイド鎮痛薬と抗てんかん薬のコーティングされた安定な固体医薬組成物
CN116898819B (zh) * 2023-06-09 2024-02-06 则正(上海)生物科技有限公司 一种普瑞巴林缓释剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
EP0951278A2 (en) * 1997-01-03 1999-10-27 ELAN CORPORATION, Plc Sustained release cisapride mini-tablet formulation
FR2781793B1 (fr) * 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
WO2003079972A2 (en) * 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20030224050A1 (en) * 2002-01-04 2003-12-04 Charles Chiao Drug delivery system for sustained delivery of glipizide
AU2006214454B2 (en) * 2005-02-15 2011-05-19 Jazz Pharmaceuticals, Inc. Dosage form and method for sustained release of a substituted pyrazine compound

Also Published As

Publication number Publication date
EP1838291A4 (en) 2008-12-03
MX2007008833A (es) 2008-03-25
KR20070116588A (ko) 2007-12-10
AR062647A1 (es) 2008-11-26
BRPI0614021A2 (pt) 2011-03-01
JP2008528494A (ja) 2008-07-31
EP1838291A2 (en) 2007-10-03
IL184735A0 (en) 2007-12-03
WO2006078811A3 (en) 2007-03-01
TW200640497A (en) 2006-12-01
CN101137352A (zh) 2008-03-05
WO2006078811A2 (en) 2006-07-27
CA2595470A1 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
AU2006206423A1 (en) Pharmaceutical formulations and methods of use
JP6328205B2 (ja) レボドパの放出制御製剤及びその使用
EP1976489B1 (en) Multiple unit type sustained release oral formulation comprising zaltoprofen and process for the preparation thereof
EP1878444B1 (en) Composition containing anti-dementia drug
KR101752014B1 (ko) 고용량 및 저용량 약물들의 조합을 포함하는 구강붕해정 조성물
AU2006297477B2 (en) Pharmaceutical dosage forms having immediate release and/or controlled release properties
US10987324B2 (en) Methods and compositions for the treatment of seizure-related disorders
TWI590835B (zh) 含有氫嗎啡酮（ｈｙｄｒｏｍｏｒｐｈｏｎｅ）和納洛酮（ｎａｌｏｘｏｎｅ）之藥學組成物
WO2021165316A1 (en) Pharmaceutical composition comprising dapagliflozin
EP2533766B1 (en) Pharmaceutical mini-tablets for sustained release of flecainide acetate
MXPA06003125A (es) Composiciones farmaceuticas de modafinilo de liberacion modificada.
WO2006123213A1 (en) Modified release formulations of gliclazide
EP2503996A2 (en) Controlled release pharmaceutical compositions of galantamine
EP3796908A1 (en) Controlled release propiverine formulations
WO2015063670A1 (en) Solid oral modified-release composition comprising oxcarbazepine or a pharmaceutically acceptable salt thereof
EP2517704B1 (en) Pharmaceutical composition for treating parkinson's disease and preparation method thereof
US20090169619A1 (en) Carbamazepine extended release dosage form
WO2015196956A1 (zh) 美托洛尔缓释组合物及其制备方法
JP2009525953A (ja) ジバルプロ酸及びその誘導体の徐放性製剤
CA3226799A1 (en) Multiparticulate pharmaceutical composition

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period